Navigation Links
U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
Date:5/15/2009

ALBANY, N.Y., May 15 /PRNewswire/ -- Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal(R), a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).

The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.

Overall, 70% of participants demonstrated significant improvement with satisfaction of treatment and Hydrosal was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success. They also experienced significant improvements in quality of life including improvement in social and professional situations.

"The key to Hydrosal's effectiveness is the gel base -- it is unique and helps balance high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is extremely pleased that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating," stated Steve Saviuk, President of Valeo Pharma.

To learn more about Hydrosal Professional, please visit www.hydrosalpro.com or contact Valeo Pharma at 866 694-0150.

To see press release go to http://myprgenie.com/1897


'/>"/>
SOURCE Valeo Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published ... approximately 800 deaths from prostate cancer, the researchers found that men who had undergone ... to get fatal prostate cancer. Although the increased risks are small, they seem to ...
(Date:2/28/2017)... Pekin, IL (PRWEB) , ... February 28, 2017 ... ... over the past decade, has challenges as they transition from military to civilian ... population of over two million who experience poorer health and greater occurrence of ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Robert E. ... large medical group. But his impoverished upbringing and life experiences could have led him ... a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, ... that occurs when the bacteria in plaque infect the gums and other tissues supporting ... and root planing or SRP, and can include surgical therapies if the condition has ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine ... programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce ... hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... ... has announced the addition of the "Ovarian Cancer Drugs Price Analysis ... The latest research Ovarian Cancer Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... clinical attributes? How are they positioned in the Global Ovarian Cancer market? ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. (Nasdaq: ... will report its fourth quarter and year end ... 7, 2017.  Rigel senior management will follow the ... at 5:00pm Eastern Time (2:00pm Pacific Time) to ... access the live conference call by dialing 855-892-1489 ...
(Date:2/28/2017)... FRANCISCO , February 27, 2017 ... D BioMedical assets for ... LOI contemplates capital infusion into Amarantus ...   Amarantus names four new appointees to its Board of ... SeD Biomedical Inc. (SeD Biomedical) , a ...
Breaking Medicine Technology: